Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CAVA Group Inc (CAVA) vs Novavax Inc (NVAX) Price & Performance

CAVA Group IncTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

CAVA Group Inc vs Novavax Inc — how do they compare? CAVA Group Inc trades at $69.34 (market cap $7.08B), while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: CAVA Group Inc is far larger — about 5.4× Novavax Inc's market cap, and CAVA Group Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

CAVANVAX
Market Cap
$7.08B$1.31B
Sector
Consumer CyclicalHealth
52-Week High
$97.39$11.19
52-Week Low
$43.59$6.22
Enterprise Value
$7.23B$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CAVA Group Inc

CAVA stock surged 12.32% to $69.165, driven by strong Q2 2026 earnings that beat estimates with $0.19 EPS and 31.3% revenue growth. Despite a bearish technical signal, fundamentals show robust expansion with same-store sales up 9% and net income margin at 4.79%. Analyst consensus remains strongly bullish with a $89.75 price target, though high valuations like a P/E of 108.59 pose concerns.

Outlook is positive due to earnings momentum and market share gains, but risks include valuation sensitivity and competitive pressures. Investors should weigh growth potential against premium multiples, with institutional support underscoring long-term confidence amid near-term volatility.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CAVA Group Inc

CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.

Read more on CAVA

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX